IQIRVO® (elafibranor)
Primary Biliary Cholangitis (PBC)
Marketed / Late-stage StudyPresenting long-term data
Key Facts
Indication
Primary Biliary Cholangitis (PBC)
Phase
Marketed / Late-stage Study
Status
Presenting long-term data
Company
About Ipsen
Ipsen is a global specialty-care biopharmaceutical company with a focused mission to develop and commercialize innovative medicines in oncology, rare diseases, and neuroscience. Under CEO David Loew, the company has achieved strong commercial execution, delivering over 9% sales growth in 2024 and upgrading guidance in 2025, underpinned by a robust balance sheet and investment-grade credit ratings. Its strategy centers on deep therapeutic area specialization, a balanced internal and external innovation model, and leveraging its unique toxin platform to build a sustainable, high-growth pipeline.
View full company profileTherapeutic Areas
Other Primary Biliary Cholangitis (PBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Setanaxib | Calliditas Therapeutics | Phase 2 |
| CNP Program | COUR Pharmaceuticals | Unknown |
| RO-7011789 (Nidufexor) | Rohto Pharmaceutical | Phase 2 |
| CNP-104 | Ironwood Pharmaceuticals | Preclinical |
| Elafibranor (GFT505) | Genfit | Phase 3 |